A股收評:繼續下探!三大指數齊跌成交額不足6500億元,工業母機、維生素板塊走高
A股主要指數今日持續下探,截至收盤,滬指跌0.44%報2950點,盤中創2月21日以來新低;深證成指跌0.83%,創業板指跌1.82%。超2800股上升,逾2300股下跌,全市場成交6482億元。盤面上,工業母機板塊爆發,恒而達等多股升停;維生素D3價格暴升,維生素板塊走高,浙江醫藥午後升停;旅遊酒店板塊走強,西藏旅遊升停;減速器、教育及房地產等板塊升幅居前。另外,半導體板塊重挫,HBM概念、汽車芯片及Chiplet概念等板塊領跌,納芯微跌超14%;3D攝像頭板塊走低,晶方科技跌近7%;AI手機板塊走弱,希荻微跌超7%;BC電池、ETC及CPO概念等跌幅居前。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.